Sweden · Delayed Price · Currency is SEK Apotea AB Statistics
Total Valuation
Apotea AB has a market cap or net worth of SEK 7.67 billion. The enterprise value is 7.88 billion.
| Market Cap | 7.67B |
| Enterprise Value | 7.88B |
Important Dates
The next confirmed earnings date is Friday, July 17, 2026.
| Earnings Date | Jul 17, 2026 |
| Ex-Dividend Date | May 27, 2026 |
Share Statistics
Apotea AB has 104.07 million shares outstanding. The number of shares has increased by 1.07% in one year.
| Current Share Class | 104.07M |
| Shares Outstanding | 104.07M |
| Shares Change (YoY) | +1.07% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 0.45% |
| Owned by Institutions (%) | 58.64% |
| Float | 73.29M |
Valuation Ratios
The trailing PE ratio is 32.47 and the forward PE ratio is 24.86.
| PE Ratio | 32.47 |
| Forward PE | 24.86 |
| PS Ratio | 1.04 |
| PB Ratio | 8.15 |
| P/TBV Ratio | 8.73 |
| P/FCF Ratio | 34.18 |
| P/OCF Ratio | 23.78 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.26, with an EV/FCF ratio of 35.10.
| EV / Earnings | 33.33 |
| EV / Sales | 1.07 |
| EV / EBITDA | 16.26 |
| EV / EBIT | 25.29 |
| EV / FCF | 35.10 |
Financial Position
The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.31.
| Current Ratio | 1.35 |
| Quick Ratio | 0.53 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 0.61 |
| Debt / FCF | 1.31 |
| Interest Coverage | 25.74 |
Financial Efficiency
Return on equity (ROE) is 28.27% and return on invested capital (ROIC) is 21.18%.
| Return on Equity (ROE) | 28.27% |
| Return on Assets (ROA) | 9.40% |
| Return on Invested Capital (ROIC) | 21.18% |
| Return on Capital Employed (ROCE) | 26.52% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 9.93M |
| Profits Per Employee | 317,608 |
| Employee Count | 744 |
| Asset Turnover | 3.57 |
| Inventory Turnover | 8.25 |
Taxes
In the past 12 months, Apotea AB has paid 66.10 million in taxes.
| Income Tax | 66.10M |
| Effective Tax Rate | 22.11% |
Stock Price Statistics
The stock price has decreased by -15.55% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -15.55% |
| 50-Day Moving Average | 72.39 |
| 200-Day Moving Average | 77.83 |
| Relative Strength Index (RSI) | 47.69 |
| Average Volume (20 Days) | 166,613 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Apotea AB had revenue of SEK 7.39 billion and earned 236.30 million in profits. Earnings per share was 2.27.
| Revenue | 7.39B |
| Gross Profit | 1.46B |
| Operating Income | 311.40M |
| Pretax Income | 299.00M |
| Net Income | 236.30M |
| EBITDA | 414.83M |
| EBIT | 311.40M |
| Earnings Per Share (EPS) | 2.27 |
Balance Sheet
The company has 104.70 million in cash and 294.50 million in debt, with a net cash position of -189.80 million or -1.82 per share.
| Cash & Cash Equivalents | 104.70M |
| Total Debt | 294.50M |
| Net Cash | -189.80M |
| Net Cash Per Share | -1.82 |
| Equity (Book Value) | 940.60M |
| Book Value Per Share | 8.88 |
| Working Capital | 361.50M |
Cash Flow
In the last 12 months, operating cash flow was 322.60 million and capital expenditures -98.20 million, giving a free cash flow of 224.40 million.
| Operating Cash Flow | 322.60M |
| Capital Expenditures | -98.20M |
| Depreciation & Amortization | 103.43M |
| Net Borrowing | -139.00M |
| Free Cash Flow | 224.40M |
| FCF Per Share | 2.16 |
Margins
Gross margin is 19.81%, with operating and profit margins of 4.21% and 3.20%.
| Gross Margin | 19.81% |
| Operating Margin | 4.21% |
| Pretax Margin | 4.05% |
| Profit Margin | 3.20% |
| EBITDA Margin | 5.61% |
| EBIT Margin | 4.21% |
| FCF Margin | 3.04% |
Dividends & Yields
This stock pays an annual dividend of 0.60, which amounts to a dividend yield of 0.81%.
| Dividend Per Share | 0.60 |
| Dividend Yield | 0.81% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.07% |
| Shareholder Yield | -0.26% |
| Earnings Yield | 3.08% |
| FCF Yield | 2.93% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Apotea AB is 90.00, which is 21.38% higher than the current price. The consensus rating is "Buy".
| Price Target | 90.00 |
| Price Target Difference | 21.38% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 11.99% |
| EPS Growth Forecast (3Y) | 22.52% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Apotea AB has an Altman Z-Score of 8.74 and a Piotroski F-Score of 6.
| Altman Z-Score | 8.74 |
| Piotroski F-Score | 6 |